1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Ennis reported results for the quarter ended May 31, 2026, with revenue of $98.6 million, up 1.4% from the prior-year quarter, and diluted earnings per share of $0.39 versus $0.38. The company also declared a quarterly dividend of 25.0 cents per share, payable August 10, 2026, and set its 2026 annual shareholder meeting for July 16, 2026.
Revenue $98.6 million vs. $97.2 million a year earlier, up 1.4%
Net earnings $9.9 million, or $0.39 per diluted share, vs. $0.38 a year earlier
Gross profit margin 31.5% vs. 31.1%; operating cash flow $21.2 million vs. $8.0 million
Quarterly dividend of 25.0 cents per share declared June 19, 2026, payable August 10, 2026 to holders of record July 10, 2026
Taysha Gene Therapies said it has completed dosing of 17 patients in its REVEAL pivotal trial of TSHA-102 for Rett syndrome and reported longer-term data from the Part A trials. The company said the data show gains in developmental milestones at 12 months and beyond, with no treatment-related serious adverse events reported, but the results are company-reported, come from small patient groups, and do not yet include an FDA decision on a BLA submission.
Dosing completed for 17 patients in the REVEAL pivotal trial; topline data from the 6-month interim analysis and FDA feedback expected in the first half of 2027.
100% of 12 REVEAL Part A patients gained or regained at least one developmental milestone by 12 months after treatment.
310 functional gains were observed at 12 months or more after treatment (about 26 per patient), including 31 developmental milestones.
No treatment-related serious adverse events or dose-limiting toxicities reported as of the June 2026 data cutoff (N=29).
On June 18, 2026, United Natural Foods and its co-borrowers entered Amendment No. 5 to their Term Loan Agreement with JPMorgan Chase Bank, N.A. as administrative agent. The amendment reduces the margin over SOFR on the approximately $371 million outstanding term loan from 4.75% to 4.00%, and all other material terms are unchanged. The change lowers the spread on the company's secured term debt, though the filing does not quantify any effect on interest expense.
Amendment No. 5 to the Term Loan Agreement dated October 22, 2018 was entered on June 18, 2026
Applicable margin over SOFR reduced from 4.75% to 4.00% on approximately $371 million outstanding
JPMorgan Chase Bank, N.A. serves as administrative and collateral agent
Full amendment to be filed as an exhibit to the Form 10-K for the year ended August 1, 2026
Arcosa agreed on June 21, 2026 to merge with a subsidiary of CRH Americas, with Arcosa surviving as a wholly owned CRH subsidiary. Each Arcosa common share would convert into $150.00 in cash, and the deal needs approval from a majority of Arcosa stockholders and regulatory clearances, with closing expected in Q1 2027. Shareholders would receive cash rather than continued ownership of Arcosa stock, and the 8-K sets out termination fees payable in both directions.
Merger consideration of $150.00 per share in cash, per the merger agreement; CRH's press release says the offer implies a 25% premium to Arcosa's 60-day trading VWAP as of June 18, 2026
Termination fee of $371,967,952 payable by CRH Americas in certain regulatory-failure cases, and $260,377,567 payable by Arcosa in certain cases including a superior proposal or change of board recommendation
Outside Date of June 21, 2027, extendable by up to six months if only antitrust or regulatory conditions remain unsatisfied
CRH press release says closing is expected in Q1 2027 and the deal is funded with available cash and committed debt financing
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.